Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

aNPC

Phase 2Small molecule

AASTEROGENE Biomedical Co. Ltd.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Degenerative Disc DiseaseNot yet recruiting

Degenerative Disc DiseasePhase 2

Not yet recruiting

Timeline

Expected Milestones

Q1 2027

Phase 1/2Not yet recruiting

Degenerative Disc Disease

NCT07168603

Clinical

Trials by Indication[1]

Degenerative Disc Disease1 trial

EvaluatIon of Autologous Nucleus Pulposus Cells (aNPC) in Degenerative Disc Disease

Not yet recruiting·AASTEROGENE Biomedical Co. Ltd.·Phase 1/2·NCT07168603·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for aNPC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — aNPC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for aNPC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ASTEROGENE Biomedical Co. Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AASTEROGENE Biomedical Co. Ltd.

Related News